The global gene therapy market is expected to expand significantly from an estimated USD 7.54 billion in 2025 to approximately USD 13.02 billion by 2031, reflecting a compound annual growth rate (CAGR) of about 9.5 percent, according to a new industry forecast report. Supportive regulatory frameworks, expedited approval pathways such as the FDA’s Regenerative Medicine Advanced Therapy and Breakthrough Therapy designations, and rising investment levels are helping accelerate commercialisation of novel gene therapy treatments led by firms such as REGENXBIO.
Regulatory agencies in key markets continue to introduce accelerated and priority review programmes, reducing the time from clinical validation to patient access and encouraging sustained industry participation. Increased funding for life sciences research is also underpinning market expansion by enabling developers to advance high-cost clinical programmes and scale manufacturing, while more than 3,200 active clinical trials for gene, cell and RNA therapies illustrate the depth of innovation underway.
Despite these growth drivers, manufacturing complexity and associated costs remain significant challenges, constraining scalability and long-term affordability. Strategic partnerships with contract development and manufacturing organisations (CDMOs) and a shift toward in vivo administration methods are emerging as industry responses to these barriers, helping developers broaden therapeutic reach into areas such as neurological conditions previously considered difficult to treat.
The report profiles several key players shaping the gene therapy landscape, including REGENXBIO, Oxford Biomedica, Voyager Therapeutics, Human Stem Cells Institute, Dimension Therapeutics, Bristol-Myers Squibb, Sanofi, F. Hoffmann-La Roche, bluebird bio, Novartis AG, and uniQure N.V., underscoring a competitive environment that spans biotech innovators and large pharmaceutical companies.
As the field evolves, continued regulatory support and funding alongside innovation in vector technology and delivery methods are expected to drive sustained growth and broaden patient access to gene-based treatments across rare diseases, cancer and other serious conditions.
